Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743
Y
Yanling Ma
F
Fei Yan
J
Jie Deng
J
Jianhai Sun
(Yanling Ma, MD, Fei Yan, MD, Jie Deng, MD, and Jianhai Sun, MD, Department of Oncology, Hubei No.3 People's Hospital of Jianghan University, Hubei, China)
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 1, Issue 1
Published
July 10, 2026
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (4)
Y
Yanling Ma
F
Fei Yan
J
Jie Deng
J
Jianhai Sun
Yanling Ma, MD, Fei Yan, MD, Jie Deng, MD, and Jianhai Sun, MD, Department of Oncology, Hubei No.3 People's Hospital of Jianghan University, Hubei, China
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001